- |||||||||| eszopiclone / Generic mfg.
The Effect of Zolpidem on Sleep Physiology and Declarative Memory over a Nap in Schizophrenia (MCP Hall A) - Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_6477;
We showed that although eszopiclone enhanced sleep spindles, it did not improve memory, potentially due to the disruption of spindle-SO coupling...Zolpidem may have increased isolated spindles, as coupled density was not affected despite an overall increase in spindle density. These findings are in line with prior research showing that coupled spindles are stronger predictors of memory than overall spindle activity.
- |||||||||| Belsomra (suvorexant) / Merck (MSD)
Retrospective data, Journal: Treatment Failure and Long-Term Prescription Risk for Guideline-Recommended Hypnotics in Japan. (Pubmed Central) - Apr 21, 2024
Due to uncontrolled confounding factors in this cohort study, no conclusions regarding the pharmacologic properties of guideline-recommended hypnotics can be drawn based on these results. Further studies accounting for confounding factors, including diagnoses of chronic vs acute insomnia disorder, insomnia and psychiatric symptom severity, and physician attitudes toward hypnotic prescription, are needed.
- |||||||||| Dayvigo (lemborexant) / Eisai
Transitioning Between Z-drugs and Lemborexant: Data from Two Studies (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3887;
P3, P4
Both studies indicate that adults with insomnia can successfully transition directly from a Z-drug to LEM. LEM was generally well tolerated.
- |||||||||| acetazolamide / Generic mfg., eszopiclone / Generic mfg.
Going From Endotypical Traits to Actual Endotypes Using a Latent Profile Analysis (San Diego Convention Center, Room 6E (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_2791;
Demographics, sleep apnea severity, sleep architecture, some patient-reported symptoms, and CPAP adherence/efficacy during the 2nd and third months differed significantly across profiles. Our preliminary analyses support the notion that OSA endotypes consist of distinct constellations of pathophysiological traits, which lead to different OSA sequelae and treatment outcomes.
- |||||||||| eszopiclone / Generic mfg., trazodone ER / Generic mfg.
Enrollment change: NAP: National Adaptive Trial for PTSD Related Insomnia (clinicaltrials.gov) - Jan 11, 2024
P3, N=774, Recruiting,
Traditional Chinese medicine can enhance the effectiveness of Western medicine in the treatment of insomnia. N=1224 --> 774
- |||||||||| Lendormin (brotizolam) / Boehringer Ingelheim, Belsomra (suvorexant) / Merck (MSD)
Journal: Trends in the multiple prescriptions of hypnotic drugs in a university outpatient in Japan. (Pubmed Central) - Nov 10, 2023
The treatment plan also has to take into account comorbidities as well as drugs used to treat them. The characteristics and success factors in relation to drug reduction in patients with multiple prescriptions of hypnotic drugs identified in this study may contribute to solving the problem of multiple prescriptions of hypnotic drugs.
- |||||||||| eszopiclone / Generic mfg.
Trial completion date, Trial primary completion date: PRECEPT-D: Effectiveness of Combining Behavioral and Pharmacologic Therapy for Complex Insomnia in Veterans With PTSD (clinicaltrials.gov) - Nov 1, 2023
P4, N=52, Recruiting,
The characteristics and success factors in relation to drug reduction in patients with multiple prescriptions of hypnotic drugs identified in this study may contribute to solving the problem of multiple prescriptions of hypnotic drugs. Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Oct 2023 --> Sep 2024
- |||||||||| eszopiclone / Generic mfg.
Journal: Improved sleep affects epigastric pain in functional dyspepsia by reducing the levels of inflammatory mediators. (Pubmed Central) - Aug 22, 2023
This study formed a consensus on rapid and effective pharmacological treatment for different symptoms of acute stress disorder pilots, which provides a reference for clinical treatment. Improving sleep with eszopiclone and/or estazolam alleviates FD-associated epigastric pain, possibly by inhibiting related downstream transmission pathways and reducing the release of inflammatory mediators.
- |||||||||| Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei, Dayvigo (lemborexant) / Eisai, Belsomra (suvorexant) / Merck (MSD)
Review, Journal: Insomnia Management: A Review and Update. (Pubmed Central) - Aug 11, 2023
Pharmacologic agents that are approved by the US Food and Drug Administration for insomnia include benzodiazepine receptor agonists (zolpidem, eszopiclone, and zaleplon), low-dose doxepin (tricyclic antidepressant), ramelteon (melatonin receptor agonist), and dual orexin receptor agonists (DORAs, daridorexant, lemborexant, and suvorexant)...Daridorexant is the newest DORA, has an ideal half-life of 8 hours, and has demonstrated continued efficacy over a 12-month period. Selection of pharmacologic agent should be based on the patient's comorbid conditions, treatment goals and preferences, and other clinical characteristics.
- |||||||||| eszopiclone / Generic mfg., diazepam / Generic mfg.
Journal: In situ construction of FeO@PDA@Au multi hotspot SERS probe for trace detection of benzodiazepines in serum. (Pubmed Central) - Jun 19, 2023
The good dispersion and superparamagnetic properties of this SERS probe enable it to fully contact and load the target molecules in the serum, and the applied magnetic field facilitates separation and enrichment.This process increases the molecular density and number of SERS hotspots, thereby enhancing detection sensitivity. Based on the above considerations, this SERS probe can detect traces of eszopiclone and diazepam in serum at concentrations as low as 1
- |||||||||| Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health
Retrospective data, Journal: Use of Daridorexant among Patients with Chronic Insomnia: A Retrospective Observational Analysis. (Pubmed Central) - May 13, 2023
No significant adverse events were noted during the study duration. Keeping in mind this study's limitations, these data suggest that for insomnia patients with an incomplete response to current therapy, switching to daridorexant is safe and may be an effective alternative treatment.
- |||||||||| Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Dayvigo (lemborexant) / Eisai
Retrospective data, Review, Journal: Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis. (Pubmed Central) - Mar 28, 2023
Lemborexant and daridorexant (two ORAs) showed greater efficacy than placebo for SL, WASO, and TST, with good tolerability...Zaleplon and eszopiclone had better efficacy than placebo for TST and SQ respectively...ORAs have superior efficacy and tolerability. These findings should aid clinicians in matching risk/benefits of drugs available in their countries to insomnia symptoms.
- |||||||||| nifedipine immediate release / Generic mfg., eszopiclone / Generic mfg., alprazolam / Generic mfg.
Journal: Evaluation of anticholinergic burden in elderly outpatients and the risk factors. (Pubmed Central) - Mar 24, 2023
There is a high rate of ACB drugs use in geriatric patients, and the clinical focus should be on multiple medication prescriptions, especially on the central nervous system drugs (such as alprazolam and eszopiclone) and cardiovascular system drugs (such as metoprolol and nifedipine). The prescription review should be emphasized to reduce adverse reactions to anticholinergic drugs in elderly patients.
- |||||||||| eszopiclone / Generic mfg., trazodone ER / Generic mfg.
Trial completion date, Trial primary completion date: NAP: National Adaptive Trial for PTSD Related Insomnia (clinicaltrials.gov) - Mar 2, 2023
P3, N=1224, Recruiting,
The prescription review should be emphasized to reduce adverse reactions to anticholinergic drugs in elderly patients. Trial completion date: Oct 2025 --> Feb 2026 | Trial primary completion date: Oct 2025 --> Feb 2026
- |||||||||| eszopiclone / Generic mfg.
Retrospective data, Review, Journal: Analgesic efficacy of sleep-promoting pharmacotherapy in patients with chronic pain: a systematic review and meta-analysis. (Pubmed Central) - Jan 27, 2023
After full-text screening, 10 RCTs (n = 574 randomized participants) involving 3 pharmacologic interventions (melatonin, zopiclone, and eszopiclone) and 7 different chronic pain populations were included...Low-quality evidence indicates that pharmacologic sleep promotion may decrease pain intensity in chronic pain populations. More research is needed to fully understand the influence of sleep-targeting interventions on pain control.
- |||||||||| Journal: Drugs for chronic insomnia. (Pubmed Central) - Jan 12, 2023
More research is needed to fully understand the influence of sleep-targeting interventions on pain control. No abstract available
- |||||||||| eszopiclone / Generic mfg.
Review, Journal: Sleep interventions for children with attention deficit hyperactivity disorder (ADHD): A systematic literature review. (Pubmed Central) - Jan 6, 2023
A moderate certainty of evidence for a moderate effect size was only obtained for sleep disturbances from the behavioral interventions. A low certainty of the evidence for a moderate effect size was found for the total sleep time from the pharmacological intervention using melatonin and one behavioral intervention, which indicates that these sleep interventions impact sleep quantity and quality among children with ADHD.
- |||||||||| Journal: Association of Benzodiazepine Treatment for Sleep Disorders With Drug Overdose Risk Among Young People. (Pubmed Central) - Nov 23, 2022
The findings of this study suggest that benzodiazepines, compared with alternative pharmacologic treatments for common sleep disorders, were associated with an increased risk of drug overdose among young people during the following 6-month period, especially among those with a recent opioid prescription. Drug overdose is an important safety consideration when treating young people with benzodiazepines.
- |||||||||| ulotaront (SEP-363856) / Sumitomo Pharma, Otsuka, dasotraline (SEP-225289) / Sumitomo Dainippon, Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Novel algorithm using incidence and duration to calculate adverse event prevalence in randomized controlled trials (Corner 1 (Hall X1) [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_1579;
Whereas the benefits of drug treatment are evaluated by dedicated efficacy measures analyzed using common statistical Methods, use of analysis Methods beyond standard incidence tables for AE data in RCTs are less commonplace. Combining AE incidence with duration offers a new way to evaluate risk to patients for treatment vs. non-treatment.
- |||||||||| ulotaront (SEP-363856) / Sumitomo Pharma, Otsuka, dasotraline (SEP-225289) / Sumitomo Dainippon, Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Novel algorithm using incidence and duration to calculate adverse event prevalence in randomized controlled trials (Poster area [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_728;
Whereas the benefits of drug treatment are evaluated by dedicated efficacy measures analyzed using common statistical Methods, use of analysis Methods beyond standard incidence tables for AE data in RCTs are less commonplace. Combining AE incidence with duration offers a new way to evaluate risk to patients for treatment vs. non-treatment.
- |||||||||| eszopiclone / Generic mfg.
Retrospective data, Review, Journal: Network meta-analysis comparing the effectiveness of a prescription digital therapeutic for chronic insomnia to medications and face-to-face cognitive behavioral therapy in adults. (Pubmed Central) - Oct 1, 2022
Twenty studies provided data on the PDT, CBT-I, CBT-I in combination with self-help (SH), or two prescription medications (eszopiclone and zolpidem)...Sensitivity analyses excluding medications and meta-regression (assessing type, duration, delivery method for CBT-I) did not affect NMA results. This network meta-analysis demonstrated that a PDT delivering CBT-I had the highest probability of being most effective compared to face-to-face CBT-I, prescription sleep medications, or placebo, as measured by reductions in mean ISI score from baseline and ISI-determined remittance.* Somryst is the registered trademark for a prescription digital therapeutics for insomnia developed by Pear Therapeutics (US), Inc.
- |||||||||| zolpidem ER / Generic mfg., eszopiclone / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: CIS2: Safety and Efficacy of Chronic Hypnotic Use 2 (clinicaltrials.gov) - Aug 24, 2022
P4, N=42, Completed,
This network meta-analysis demonstrated that a PDT delivering CBT-I had the highest probability of being most effective compared to face-to-face CBT-I, prescription sleep medications, or placebo, as measured by reductions in mean ISI score from baseline and ISI-determined remittance.* Somryst is the registered trademark for a prescription digital therapeutics for insomnia developed by Pear Therapeutics (US), Inc. Recruiting --> Completed | N=120 --> 42 | Trial completion date: Dec 2023 --> Feb 2022 | Trial primary completion date: Jul 2023 --> Feb 2022
- |||||||||| Trial completion date, Trial initiation date, Trial primary completion date: RescOSA: Rescue Pharmacotherapy for OSA (clinicaltrials.gov) - Jul 20, 2022
P1/2, N=70, Not yet recruiting,
Both offer potential new insight for treating insomnia. Trial completion date: Sep 2022 --> Jul 2024 | Initiation date: May 2022 --> Sep 2022 | Trial primary completion date: Jul 2022 --> Dec 2023
|
